AstraZeneca starts the Cellectis partnership with $105 million in upfront cash and an equity investment. The pharmaceutical giant will also cover research costs for up to 10 cell therapy programs in oncology, immunology, and rare diseases.
New AstraZeneca, Cellectis Alliance Spans Up to 10 Cell & Gene Therapies
